These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

27 related articles for article (PubMed ID: 20844484)

  • 1. Identification of natural products as modulators of OATP2B1 using LC-MS/MS to quantify OATP-mediated uptake.
    Wen F; Shi M; Bian J; Zhang H; Gui C
    Pharm Biol; 2016; 54(2):293-302. PubMed ID: 25858254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of metabolic state and body composition on the action of pharmacological treatment of migraine.
    Bruijn N; van Lohuizen R; Boron M; Fitzek M; Gabriele F; Giuliani G; Melgarejo L; Řehulka P; Sebastianelli G; Triller P; Vigneri S; Özcan B; van den Brink AM;
    J Headache Pain; 2024 Feb; 25(1):20. PubMed ID: 38347465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (Thyroid) Hormonal regulation of breast cancer cells.
    Hercbergs A; Lin HY; Mousa SA; Davis PJ
    Front Endocrinol (Lausanne); 2022; 13():1109555. PubMed ID: 36714596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrabromobisphenol A (TBBPA) Alters ABC Transport at the Blood-Brain Barrier.
    Cannon RE; Trexler AW; Knudsen GA; Evans RA; Birnbaum LS
    Toxicol Sci; 2019 Jun; 169(2):475-484. PubMed ID: 30830211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid hormone and anti-apoptosis in tumor cells.
    Lin HY; Glinsky GV; Mousa SA; Davis PJ
    Oncotarget; 2015 Jun; 6(17):14735-43. PubMed ID: 26041883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid hormone and P-glycoprotein in tumor cells.
    Davis PJ; Incerpi S; Lin HY; Tang HY; Sudha T; Mousa SA
    Biomed Res Int; 2015; 2015():168427. PubMed ID: 25866761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac.
    Davis PJ; Glinsky GV; Lin HY; Leith JT; Hercbergs A; Tang HY; Ashur-Fabian O; Incerpi S; Mousa SA
    Front Endocrinol (Lausanne); 2014; 5():240. PubMed ID: 25628605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digoxin - a therapeutic agent and mechanistic probe: review of liquid chromatographic mass spectrometric methods and recent nuances in the clinical pharmacology attributes of digoxin.
    Srinivas NR; Ramesh M
    Bioanalysis; 2009 Apr; 1(1):97-113. PubMed ID: 21083191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.
    O'Connor P; Feely J
    Clin Pharmacokinet; 1987 Dec; 13(6):345-64. PubMed ID: 3325214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin.
    Burk O; Brenner SS; Hofmann U; Tegude H; Igel S; Schwab M; Eichelbaum M; Alscher MD
    Clin Pharmacol Ther; 2010 Nov; 88(5):685-94. PubMed ID: 20844484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition.
    Siegmund W; Altmannsberger S; Paneitz A; Hecker U; Zschiesche M; Franke G; Meng W; Warzok R; Schroeder E; Sperker B; Terhaag B; Cascorbi I; Kroemer HK
    Clin Pharmacol Ther; 2002 Sep; 72(3):256-64. PubMed ID: 12235446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
    Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
    Larsen UL; Hyldahl Olesen L; Guldborg Nyvold C; Eriksen J; Jakobsen P; Østergaard M; Autrup H; Andersen V
    Scand J Clin Lab Invest; 2007; 67(2):123-34. PubMed ID: 17365992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects.
    Shoaf SE; Ohzone Y; Ninomiya S; Furukawa M; Bricmont P; Kashiyama E; Mallikaarjun S
    J Clin Pharmacol; 2011 May; 51(5):761-9. PubMed ID: 20679500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of continuous exposure to digoxin on MDR1 function and expression in Caco-2 cells.
    Takara K; Tsujimoto M; Ohnishi N; Yokoyama T
    J Pharm Pharmacol; 2003 May; 55(5):675-81. PubMed ID: 12831511
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.